HomeNewsBusinessEarningsSpiceJet widens net loss for September quarter to Rs 838 crore

SpiceJet widens net loss for September quarter to Rs 838 crore

The airline reported a net loss of Rs 577.7 crore in Q2FY2023. It had reported a net loss of Rs 561.7 crore in the second quarter of 2021-22.

November 15, 2022 / 08:12 IST
Story continues below Advertisement

SpiceJet Ltd on November 14 released its second-quarter results (July-September period) for the fiscal year 2022-23. The airline reported a net loss of Rs 837.8 crore for Q2FY2023. The low-cost carrier had reported a net loss of Rs 561.7 crore in the second quarter of 2021-22.

Out of the total loss, Rs 260 crore in losses was due to foreign exchange currency loss, the airline said in a press release.

Story continues below Advertisement

Foreign exchange losses have played a significant part in eroding the earnings of both SpiceJet and IndiGo.

However, while SpiceJet’s revenue from operations was one-sixth of IndiGo’s in the July-September quarter, its loss was half of what IndiGo reported.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show